ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,205.51
0.41%
Dow Jones
38,225.66
0.85%
Gold vs US Dollar
2,300.775
-0.12%
Brent Oil
83.555
-0.09%
Bitcoin
59,453.41
0.56%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Tarsus Pharmaceuticals Inc (TARS)

  7. Tarsus Pharmaceuticals Inc (TARS) News

Tarsus Pharmaceuticals (TARS)

Tarsus Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:TARS
DateTimeSourceHeadlineSymbolCompany
01/05/202422:00GlobeNewswire Inc.Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024NASDAQ:TARSTarsus Pharmaceuticals Inc
23/04/202413:30GlobeNewswire Inc.Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from PharmakonNASDAQ:TARSTarsus Pharmaceuticals Inc
11/03/202421:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
11/03/202421:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
11/03/202421:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
11/03/202421:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
05/03/202421:30GlobeNewswire Inc.Tarsus to Participate at Upcoming Investor ConferencesNASDAQ:TARSTarsus Pharmaceuticals Inc
05/03/202421:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TARSTarsus Pharmaceuticals Inc
05/03/202413:30GlobeNewswire Inc.Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex BlepharitisNASDAQ:TARSTarsus Pharmaceuticals Inc
01/03/202422:26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TARSTarsus Pharmaceuticals Inc
01/03/202422:17Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:TARSTarsus Pharmaceuticals Inc
01/03/202405:07GlobeNewswire Inc.Tarsus Announces Pricing of $100.0 Million Public OfferingNASDAQ:TARSTarsus Pharmaceuticals Inc
29/02/202422:08Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:TARSTarsus Pharmaceuticals Inc
29/02/202421:37GlobeNewswire Inc.Tarsus Announces Proposed $100.0 Million Public OfferingNASDAQ:TARSTarsus Pharmaceuticals Inc
29/02/202421:32Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:TARSTarsus Pharmaceuticals Inc
27/02/202421:22Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TARSTarsus Pharmaceuticals Inc
27/02/202421:02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:TARSTarsus Pharmaceuticals Inc
27/02/202411:00GlobeNewswire Inc.Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business AchievementsNASDAQ:TARSTarsus Pharmaceuticals Inc
22/02/202413:00GlobeNewswire Inc.Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme DiseaseNASDAQ:TARSTarsus Pharmaceuticals Inc
20/02/202422:00GlobeNewswire Inc.Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024NASDAQ:TARSTarsus Pharmaceuticals Inc
31/01/202422:00GlobeNewswire Inc.Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks ConferenceNASDAQ:TARSTarsus Pharmaceuticals Inc
30/01/202421:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
22/01/202422:05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TARSTarsus Pharmaceuticals Inc
18/01/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TARSTarsus Pharmaceuticals Inc
08/01/202414:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TARSTarsus Pharmaceuticals Inc
29/12/202322:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
27/12/202321:23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
22/12/202322:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
20/12/202321:49Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
19/12/202323:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:TARS

Your Recent History

LSE
TERN
Tern
LSE
AGL
Angle
LSE
AAZ
Anglo Asian Mining
LSE
SCLP
Scancell
LSE
POS
Plexus
LSE
ZPHR
Zephyr Energy
LSE
OBI
Ondine Biomedical
LSE
IES
Invinity Energy Systems
LSE
DGI
Dg Innovate
LSE
AAU
Ariana Resources
LSE
SCE
Surface Transforms
LSE
BIRD
Blackbird
LSE
W7L
Warpaint London
LSE
LLOY
Lloyds Banking
LSE
GFM
Griffin Mining
LSE
MIRI
Mirriad Advertising
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved